SCHEMBL5374243

SCHEMBL5374243

CCOC(=O)c1ccc(CSc2nnc(Nc3ccc(F)cc3)[nH]2)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
HPGD P15428 2/20 0.48
POLB P06746 1/20 0.48
KDM4E B2RXH2 4/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
ESR1 P03372 1/20 0.45
CREBBP Q92793 1/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 6/20 0.44
LMNA P02545 4/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44
RAB9A P51151 3/20 0.43
GFER P55789 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 3/20 0.42
HTT P42858 2/20 0.42
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371958 0.92 ALDH1A1 (0.56) ALDH1A1HPGDPOLBKDM4EHSD17B10
SCHEMBL5376644 0.90 ALDH1A1 (0.56) ALDH1A1HPGDPOLBKDM4EHSD17B10
SCHEMBL5376856 0.85 ALDH1A1 (0.52) ALDH1A1HPGDPOLBHSD17B10GAA
SCHEMBL5378895 0.83 ALDH1A1 (0.54) ALDH1A1HPGDPOLBHSD17B10GAA
SCHEMBL5380976 0.82 ALDH1A1 (0.56) ALDH1A1HPGDPOLBHSD17B10USP2
SCHEMBL5377203 0.80 ALDH1A1 (0.51) ALDH1A1HPGDPOLBHSD17B10GAA
SCHEMBL6404847 0.75 ALDH1A1 (0.59) ALDH1A1HPGDPOLBKDM4EHSD17B10
SCHEMBL6405948 0.72 ALDH1A1 (0.55) ALDH1A1HPGDPOLBKDM4EHSD17B10
SCHEMBL4677310 0.70 HDAC4 (0.54) ALDH1A1HPGDPOLBKDM4EHSD17B10
SCHEMBL26910790 0.67 ALDH1A1 (0.59) ALDH1A1HPGDPOLBKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US claimed
EP-1223932-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2003-01-15 EP claimed
EP-1223932-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2002-07-24 EP claimed
WO-2001024796-A1 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE SMITHKLINE BEECHAM CORPORATION (US) 2001-04-12 WO claimed
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US disclosed
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION 2005-12-01 US disclosed
EP-1223932-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2003-01-15 EP disclosed
EP-1223932-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2002-07-24 EP disclosed
WO-2001024796-A1 1,2,4-TRIAZOLE DERIVATIVES, COMPOSITION, PROCESS OF MAKING AND METHODS OF USE SMITHKLINE BEECHAM CORPORATION (US) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use METAP2, METAP1, DNPEP ALDH1A1 1754/4885HPGD 2062/4885POLB 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.